New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 13, 2012
11:49 EDTQCORQuestcor down 6% following presentation at investor conference
Shares of biopharmaceutical company Questcor Pharmaceuticals (QCOR) slid in mid-morning trading as the company presented at the JMP Securities Healthcare Conference. During the presentation, the company's Chief Scientific Officer discussed the mechanism of action and unique biological and clinical properties of the company's primary product, Acthar Gel. The company also focused on its strategic plan to focus on "the embedded pipeline in Acthar," highlighting its research and development plans. Investors may have been disappointed that the company did not directly speak to allegations recently made by short sellers, specifically the accusations made by Citron Research in a report published July 10. In mid-morning trading, Questcor fell $2.88, or 6.33%, to $42.60 after being up marginally at the open.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 25, 2014
13:13 EDTQCOREinhorn bought Lam Research shares, sold Rite Aid last quarter
Subscribe for More Information
12:18 EDTQCORGreenlight discloses short positions in Safeway, Questcor, Bloomberg says
Subscribe for More Information
10:02 EDTQCOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:22 EDTQCORQuestcor downgraded to Perform from Outperform at Oppenheimer
July 24, 2014
09:10 EDTQCORQuestcor expects insurance coverage for Acthar to remain favorable, consistent
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 H.P. Acthar gel sales up 39% to $188.5M
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 adjusted EPS $1.85, consensus $1.74
Subscribe for More Information
July 21, 2014
07:36 EDTQCORMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information
July 17, 2014
11:12 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
July 16, 2014
16:13 EDTQCORMallinckrodt initiated with an Outperform, $100 target at Oppenheimer
Oppenheimer believes Mallinckrodt's (MNK) acquisition of Questcor (QCOR) provides sustainable high-growth revenue potential. It believes the company bought Acthar at an attractive valuation. Opco started shares of Mallinckrodt with an Outperform rating and $100 price target.
10:35 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
July 14, 2014
15:09 EDTQCORQuestcor rises after S-4 effective, interest from other suitors disclosed
Subscribe for More Information
07:04 EDTQCORMallinckrodt and Questcor update transaction
Mallinckrodt (MNK) and Questcor (QCOR) announced that the registration statement on Form S-4 filed with the SEC by Mallinckrodt on May 16 and amended on July 11 which includes a joint proxy statement of Mallinckrodt and Questcor that also constitutes a prospectus of Mallinckrodt, was declared effective on July 11. The companies have also each scheduled shareholder meetings on August 14 for shareholders of record on July 9 to consider (i) in the case of Mallinckrodt, its proposal to issue its ordinary shares in connection with its proposed acquisition of Questcor and (ii) in the case of Questcor, approval of the merger agreement with Mallinckrodt and related matters. The transaction is currently expected to be completed in August.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use